Intermittent levosimendan infusions in advanced heart failure: a real world experience

Benedetta Ortis, Alessandra Villani, Matteo Oldani, Alessia Giglio, Francesca Ciambellotti, Mario Facchini, Gianfranco Parati, Gabriella Malfatto

Research output: Contribution to journalArticle

Abstract

Objective: To analyse the effects of levosimendan infusions in advanced heart failure. Methods: Patients with advanced heart failure treated with repeated levosimendan infusions were retrospectively compared with controls. Clinical, blood and echocardiographic parameters were obtained at baseline and after 12 months, and before and after each levosimendan infusion. Hospitalizations for heart failure and in-hospital length of stay in the 6 months before enrolment and after 6 and 12 months were recorded, along with 1-year mortality. Results: Twenty-five patients treated with levosimendan and 25 controls were studied. After each levosimendan infusion, ventricular function and various clinical and metabolic parameters were improved. After 12 months, left ventricular ejection fraction (LVEF) had improved compared with baseline in the levosimendan group. The 1-year mortality rate was similar in both groups. During the 6 months before enrolment, hospitalizations were fewer in controls compared with the levosimendan group; after 6 and 12 months they increased in controls and decreased in the levosimendan group. Seven patients were super-responders to levosimendan, with LVEF improving more than 20% and hospitalizations being reduced at 12 months compared with the rest of the levosimendan group. Conclusion: Intermittent levosimendan improved LVEF and decreased hospitalizations in advanced heart failure and represents a therapeutic option for patients whose disease is worsening.

Original languageEnglish
Pages (from-to)361-371
Number of pages11
JournalJournal of International Medical Research
Volume45
Issue number1
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Heart Failure
Hospitalization
Stroke Volume
Length of Stay
simendan
Ventricular Function
Mortality
Blood

Keywords

  • Advanced chronic heart failure
  • inotropic drugs
  • intermittent levosimendan

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

Intermittent levosimendan infusions in advanced heart failure : a real world experience. / Ortis, Benedetta; Villani, Alessandra; Oldani, Matteo; Giglio, Alessia; Ciambellotti, Francesca; Facchini, Mario; Parati, Gianfranco; Malfatto, Gabriella.

In: Journal of International Medical Research, Vol. 45, No. 1, 01.02.2017, p. 361-371.

Research output: Contribution to journalArticle

Ortis, Benedetta ; Villani, Alessandra ; Oldani, Matteo ; Giglio, Alessia ; Ciambellotti, Francesca ; Facchini, Mario ; Parati, Gianfranco ; Malfatto, Gabriella. / Intermittent levosimendan infusions in advanced heart failure : a real world experience. In: Journal of International Medical Research. 2017 ; Vol. 45, No. 1. pp. 361-371.
@article{f3731ef501274c13a161e8890efbfd47,
title = "Intermittent levosimendan infusions in advanced heart failure: a real world experience",
abstract = "Objective: To analyse the effects of levosimendan infusions in advanced heart failure. Methods: Patients with advanced heart failure treated with repeated levosimendan infusions were retrospectively compared with controls. Clinical, blood and echocardiographic parameters were obtained at baseline and after 12 months, and before and after each levosimendan infusion. Hospitalizations for heart failure and in-hospital length of stay in the 6 months before enrolment and after 6 and 12 months were recorded, along with 1-year mortality. Results: Twenty-five patients treated with levosimendan and 25 controls were studied. After each levosimendan infusion, ventricular function and various clinical and metabolic parameters were improved. After 12 months, left ventricular ejection fraction (LVEF) had improved compared with baseline in the levosimendan group. The 1-year mortality rate was similar in both groups. During the 6 months before enrolment, hospitalizations were fewer in controls compared with the levosimendan group; after 6 and 12 months they increased in controls and decreased in the levosimendan group. Seven patients were super-responders to levosimendan, with LVEF improving more than 20{\%} and hospitalizations being reduced at 12 months compared with the rest of the levosimendan group. Conclusion: Intermittent levosimendan improved LVEF and decreased hospitalizations in advanced heart failure and represents a therapeutic option for patients whose disease is worsening.",
keywords = "Advanced chronic heart failure, inotropic drugs, intermittent levosimendan",
author = "Benedetta Ortis and Alessandra Villani and Matteo Oldani and Alessia Giglio and Francesca Ciambellotti and Mario Facchini and Gianfranco Parati and Gabriella Malfatto",
year = "2017",
month = "2",
day = "1",
doi = "10.1177/0300060516655244",
language = "English",
volume = "45",
pages = "361--371",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "1",

}

TY - JOUR

T1 - Intermittent levosimendan infusions in advanced heart failure

T2 - a real world experience

AU - Ortis, Benedetta

AU - Villani, Alessandra

AU - Oldani, Matteo

AU - Giglio, Alessia

AU - Ciambellotti, Francesca

AU - Facchini, Mario

AU - Parati, Gianfranco

AU - Malfatto, Gabriella

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Objective: To analyse the effects of levosimendan infusions in advanced heart failure. Methods: Patients with advanced heart failure treated with repeated levosimendan infusions were retrospectively compared with controls. Clinical, blood and echocardiographic parameters were obtained at baseline and after 12 months, and before and after each levosimendan infusion. Hospitalizations for heart failure and in-hospital length of stay in the 6 months before enrolment and after 6 and 12 months were recorded, along with 1-year mortality. Results: Twenty-five patients treated with levosimendan and 25 controls were studied. After each levosimendan infusion, ventricular function and various clinical and metabolic parameters were improved. After 12 months, left ventricular ejection fraction (LVEF) had improved compared with baseline in the levosimendan group. The 1-year mortality rate was similar in both groups. During the 6 months before enrolment, hospitalizations were fewer in controls compared with the levosimendan group; after 6 and 12 months they increased in controls and decreased in the levosimendan group. Seven patients were super-responders to levosimendan, with LVEF improving more than 20% and hospitalizations being reduced at 12 months compared with the rest of the levosimendan group. Conclusion: Intermittent levosimendan improved LVEF and decreased hospitalizations in advanced heart failure and represents a therapeutic option for patients whose disease is worsening.

AB - Objective: To analyse the effects of levosimendan infusions in advanced heart failure. Methods: Patients with advanced heart failure treated with repeated levosimendan infusions were retrospectively compared with controls. Clinical, blood and echocardiographic parameters were obtained at baseline and after 12 months, and before and after each levosimendan infusion. Hospitalizations for heart failure and in-hospital length of stay in the 6 months before enrolment and after 6 and 12 months were recorded, along with 1-year mortality. Results: Twenty-five patients treated with levosimendan and 25 controls were studied. After each levosimendan infusion, ventricular function and various clinical and metabolic parameters were improved. After 12 months, left ventricular ejection fraction (LVEF) had improved compared with baseline in the levosimendan group. The 1-year mortality rate was similar in both groups. During the 6 months before enrolment, hospitalizations were fewer in controls compared with the levosimendan group; after 6 and 12 months they increased in controls and decreased in the levosimendan group. Seven patients were super-responders to levosimendan, with LVEF improving more than 20% and hospitalizations being reduced at 12 months compared with the rest of the levosimendan group. Conclusion: Intermittent levosimendan improved LVEF and decreased hospitalizations in advanced heart failure and represents a therapeutic option for patients whose disease is worsening.

KW - Advanced chronic heart failure

KW - inotropic drugs

KW - intermittent levosimendan

UR - http://www.scopus.com/inward/record.url?scp=85012202200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012202200&partnerID=8YFLogxK

U2 - 10.1177/0300060516655244

DO - 10.1177/0300060516655244

M3 - Article

C2 - 28222634

AN - SCOPUS:85012202200

VL - 45

SP - 361

EP - 371

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 1

ER -